Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice
, Silvio Ken Garattini 2, Marika Cinausero 2, Marianna Macerelli 2, Martina Fanelli 2, Fabio Puglisi 1,3, Gianpiero Fasola 2 and Paola Ermacora 2
Round 1
Reviewer 1 Report
In their manuscript: “Rare and insidious toxicities from new combination therapies in metastatic renal cell cancer: lessons learned from real-practice”, Der et al. describe adverse events from combined therapies by two RCC patients. Their aim was to assign the therapy-related toxicities and discontinue for the patient burdensome treatment. The article is well structured; description of both cases provides sufficient information. The discussion reviews the current knowledge about the possible adverse events appearing during the therapy. I would suggest to include both cases more in the discussion.
Author Response
Please see the attachment.
Author Response File: 
Author Response.docx
Reviewer 2 Report
Dri et al. describe their experience dealing with rare toxicities coming from combination of immunotherapy and tyrosine kinase inhibitor. They describe two cases and, mostly, provide to readers recommendations on the management of adverse effects.
The cases are well described, well illustrated and well summarized through a clear flow-chart reporting precisely the timeline. IMHO, this elegant table represents and added value.
The discussion encompasses many items and provide useful pieces of information to the oncologists about the management of toxicities.
This manuscript does not need any modifications and it is worthy of publication as it is.
Author Response
Thank you for your kind review.
